ELFIN study number: (SIFT study number:			



Form 3: Late-Onset Invasive Infection



Use this form:

To report each episode of **microbiologically-confirmed** (Section A) or **clinically-suspected** (Section B, overleaf) late-onset invasive infection

Infa Infa	nt's surname: nt's first name: (enter unl nt's date of birth: ne of hospital:	known if applicable)	DD/MM/YY
Sec A.1	ction A: Microbiolog Details of samples show	jically-confirmed late-onset invas	sive infection
	Site (blood or CSF)	Name of organism	Date of sample
			DD/MM/YY
A.2		is infant treated with antibiotics for this e d number of days if this infant died during tre	_
A.3	Date antibiotics started	:	DD/MM/YY
A.4	Date antibiotics stopped	d:	DD/MM/YY
	If available, please provid	de a copy of the microbiology report	
A.5		is infant treated with antifungals for this nded number of days if this infant died during prophylactic doses)	g
A.6	Date antifungals started	1 :	DD/MM/YY
A.7	Date antifungals stoppe	ed:	DD/MM/YY
Mic Mic - po con - fui ANI	otentially pathogenic bacteria (inc taminants such as diphtheroids, ngi D	-onset Invasive Infection or CSF sampled aseptically more than 72 hours after be cluding coagulase-negative Staphylococci species but micrococci, propionibacteria or a mixed flora) ontravenous antibiotics after the above investigation wa	t excluding probable skin
died wou	d, was discharged, or was transfould still be met if the intention wa	erred prior to the completion of 5 days of intravenous	antibiotics, this condition

IN stud	dy number:	SIFT study number:
Sec	ction B: Clinically-suspected late-onset invasiv	ve infection
	initions:	
Eith	ner - Absence of positive microbiological culture, OR - culture of a mixed micr	robial flora or of likely skin
CON	taminants (diphtheroids, micrococci, propionibacteria) only.	
Clin	_ nician intent to administer antibiotic treatment or intravenous antifungals for 5	
	imicrobial prophylaxis) for an infant who demonstrates 3 or more of the follov asive infection:	ving clinical or laboratory features of
B.1	Please specify reasons for antibiotic treatment (tick all bo	xes that apply)
	Increase in oxygen requirement or ventilatory support	
	Increase in frequency of episodes of bradycardia or apnoe	ea
	Temperature instability	
	lleus or enteral feeds intolerance and/or abdominal distent	tion
	Reduced urine output to <1 ml/kg/hour	
	Impaired peripheral perfusion (capillary refill time >3 secon	nds, skin
	mottling or core-peripheral temperature gap >2°C)	
	Hypotension (clinician defined as needing volume or inotro	ope support)
	Irritability, lethargy or hypotonia (clinician-defined)	
	Increase in serum C-reactive protein levels to >15 mg/l or	procalcitonin ≥2 ng/ml;
	White blood cells count <4 or >20 × 109 cells/l or platelet c	ount <100 × 10 ⁹ /I
	Glucose intolerance (blood glucose <2.2 mmol/l or >10 mr	mol/l)
	Metabolic acidosis (base excess <-10 mmol/l or lactate >2	mmol/l)
B.2	How many days was this infant treated with antibiotics for	
	(please state the intended number of days if this infant died of	luring treatment)
B.3	Date antibiotics started:	DD/MM/YY
B.4	Date antibiotics stopped:	DD/MM/YY
B.5	How many days was this infant treated with antifungals f	
	episode? (State the intended number of days if this infant die treatment, do not include prophylactic doses)	ed during
B.6	Date antifungals started:	DD/MM/YY
B.7	Date antifungals stopped:	D D / M M / Y Y
	on C: Form details	
Deta	ails of person completing form	
Nan	ne: Role:	
Date		
Prin	ncipal Investigator Signature:	
	NPEU Clinical Trials Unit, National Perinatal Epidemiology Ur	nit, University of Oxford
	Old Road Campus, Oxford, OX3 7LF 01865 289 740 elfin@npeu.ox.ac.uk sift@	ארו טא אט ווא
	www.npeu.ox.ac.uk/elfin www.npeu.ox.ac	
(Ľ		





